A Phase II Clinical Study of 15-moderate-hypofractionated Helical Tomotherapy in Elderly Patients with Prostate Cancer

A Phase II Clinical Study of moderate-hypofractionated Helical Tomotherapy in Elderly Patients with Prostate Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400083572

Enrollment

Unknown

Registered

2024-04-28

Start date

2024-05-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

1:moderate-hypofractionated Helical Tomotherapy

Eligibility

Sex/Gender

Male

Age

60 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Localized prostate cancer (according to AJCC 8th TNM stage, excluding regional and distant metastasis) , 2. Over 60 years old, 3. Expected survival over 5 years, 4. WHO survival status 0-2; 5. Signing informed consent; 6. Allowing endocrine therapy.

Exclusion criteria

Exclusion criteria: 1. Radical prostatectomy; 2. Distant metastasis; 3. Previous radiotherapy in the target area; 4. Severe complications; 5. Expected survival of less than 5 years.

Design outcomes

Primary

Measure	Time frame
Late toxic and side effects of intestinal and urinary system;Prostate-specific survival;Overall survival;Early toxic and side effects of intestinal and urinary system;	—

Secondary

Measure	Time frame
Failure-free lifetime;	—

Countries

China

Contacts

Public ContactLingling Meng

Meng Lingling

mll301@126.com+86 138 1167 0794

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026